A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Inclusion Criteria:

* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART)
* If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks
* If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load
* Has adequate organ function

Exclusion Criteria:

* If prior anticancer therapy is allowed, participants are excluded if they received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before allocation
* Has received prior locoregional therapy within 2 weeks of start of study intervention, or has ongoing locoregional treatment-related toxicities
* Is currently receiving any anticoagulants
* Was discontinued from prior immunotherapy due to a Grade ≥3 immune-related adverse event (irAE)
* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
* Has known additional malignancy that is progressing or has required active treatment within the past 2 years
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments
* Active or ongoing stomatitis and/or mucositis of any grade
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
* Has history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has history of stem cell/solid organ transplant
* Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
* Has clinically significant hemoptysis, hematemesis, or tumor bleeding within 4 weeks before the first dose of study intervention
* Has any clinically significant or life-threatening bleeding event that occurred within 3 months prior to the first dose of the study intervention
* Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
* Has any history of myocarditis or cardiomyopathy
* Has a current or history of severe cardiovascular and cerebrovascular diseases